Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) have been assigned a consensus recommendation of “Moderate Buy” from the eleven ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $42.4286.

A number of research analysts recently issued reports on the company. HC Wainwright assumed coverage on Damora Therapeutics, Inc. Common Stock in a research note on Thursday, June 11th. They set a “buy” rating and a $45.00 price target on the stock. Royal Bank Of Canada initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Friday, April 24th. They set an “outperform” rating and a $40.00 price objective on the stock. Wedbush reissued an “outperform” rating and set a $35.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research report on Friday, June 12th. TD Cowen assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, June 8th. They set a “buy” rating on the stock. Finally, Evercore assumed coverage on Damora Therapeutics, Inc. Common Stock in a research note on Wednesday, March 25th. They issued an “outperform” rating and a $46.00 target price on the stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Janus Henderson Group PLC purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at approximately $40,000. Geode Capital Management LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter worth about $266,000. Virtu Financial LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the third quarter worth about $49,000. Sigma Planning Corp acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter worth about $334,000. Finally, Two Sigma Investments LP acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the third quarter worth about $76,000. 14.20% of the stock is currently owned by hedge funds and other institutional investors.

Damora Therapeutics, Inc. Common Stock Price Performance

NASDAQ DMRA opened at $21.23 on Friday. The firm’s fifty day moving average price is $24.18 and its 200 day moving average price is $25.51. The company has a market capitalization of $1.31 billion, a price-to-earnings ratio of -3.80 and a beta of 1.46. Damora Therapeutics, Inc. Common Stock has a 12 month low of $2.45 and a 12 month high of $38.33.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last posted its earnings results on Wednesday, May 13th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.23). As a group, sell-side analysts forecast that Damora Therapeutics, Inc. Common Stock will post -1.92 earnings per share for the current year.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical?stage biotechnology company developing small?molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin?3, an extracellular carbohydrate?binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase?like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin?3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin?3 inhibitor being evaluated for systemic fibrotic disorders.